Chronic non-A, non-B hepatitis: role of hepatitis C virus

R Iorio, S Guida, S Porzio, I Fariello, A Vegenente

Abstract
Thirty three consecutive children with chronic non-A, non-B hepatitis (NANBH) were studied during a four year period to evaluate clinical and histological features and the role of hepatitis C virus (HCV). All patients were asymptomatic. Thirteen (39%) of them were anti-HCV positive. A history of parenteral exposure was significantly more frequent among anti-HCV positive (69%) than anti-HCV negative patients (15%). Aminotransferase serum values were not statistically different between anti-HCV positive and anti-HCV negative patients. Unlike adults, cirrhosis was never found in the children studied. Our results suggest that chronic NANBH is, during childhood, an asymptomatic disease and that the prevalence of HCV infection is lower than in adults. As the majority of the children with chronic NANBH showed no evidence of HCV infection, it seems unwarranted to identify NANBH with HCV infection in children. The lack of cirrhosis in paediatric patients is probably related to a shorter duration of liver disease.

(Arch Dis Child 1993;68:219–22)

Non-A, non-B hepatitis (NANBH) accounts for 90% of post-transfusion hepatitis and for about 20–40% of cases of sporadic hepatitis.1 With the discovery of a test for antibodies to hepatitis C virus (HCV) it has been found that almost all post-transfusion hepatitis and about 50% of sporadic NANBH is caused by this virus.2–4 NANBH, including HCV infection, becomes chronic in more than 50% of infected individuals and in more than 20% of chronic cases histological evidence of cirrhosis is found.5 In adulthood, where intravenous drug use and sexual activity together have an important role in the spreading of NANBH, at least 40% of patients with NANBH have no known source of infection.6 On the other hand, scanty information is available about NANBH in childhood. Although studies have been performed concerning epidemiology7–9 and treatment (M Ruiz-Moreno et al, work presented at the 24th Annual Meeting of the European Society for Paediatric Gastroenterology and Nutrition, London, June 5–7, 1991) of the disease, few data have been reported about clinical features, histology, and natural history in paediatric patients. The present study was undertaken with the aim of assessing the clinical picture of chronic NANBH in childhood and the role of HCV, and to identify possible differences in epidemiology, clinical features, and histology between anti-HCV positive and anti-HCV negative children.

Patients and methods
We have studied 33 consecutive children (18 boys, 15 girls; mean age 7–6 years, range 1–4–13–2 years) with chronic NANBH who were seen in the department of paediatrics at the University of Naples during a four year period (1987–91). Diagnosis of chronic NANBH was made when high serum values of aminotransferases persisted for more than six months in the absence of known causes (that is, infectious, metabolic, autoimmune, neoplastic, toxic, non-hepatic). In the patients studied the mean duration of chronic NANBH was four years (range 0–6–10–0 years). None of them had a history of acute hepatitis, 27 (82%) showed raised aminotransferase serum values for the first time at routine check up before a minor surgical procedure (such as adenoidectomy or tonsillectomy); four (12%) came to observation for non-specific symptoms of liver disease (for example anorexia, asthenia, abdominal pain). Finally, two (6%) were identified during family screening for viral hepatitis as their mothers showed evidence of NANBH and hepatitis C, respectively.

The mean age of patients at the first detection of hypertransaminasaemia was 3–6 years (range 0–3–9–7 years). In all patients clinical features and nutritional status were carefully evaluated. Weight was expressed as percentage of expected weight at a given height for the 50th centile.10 11 Height, measured with the Harpenden stadiometer, was expressed as percentage of expected height for age (that is, percent of 50th centile).10 11 The standards of the National Center for Health Statistics were used for assessment.12 According to Waterlow criteria,11 13 we have considered, in addition to normal, three possible degrees of malnutrition and three degrees of height stunting. In all patients liver function tests were carried out by standard methods, and antibodies to HCV were detected with a recombinant assay for anti-HCV (RIBA-2, Ortho Diagnostic Systems). The other causes of hypertransaminasaemia were excluded by conventional methods. As it has been reported that reduced IgA serum concentrations are frequently present in patients with chronic autoimmune hepatitis type-2,14 who are in turn anti-HCV positive in the 80% of cases,15 we have tested serum immunoglobulin concentrations in the patients studied with commercially available assays (Accra Assay RID Kits). In all patients ultrasound scanning was performed by...
using high resolution real time scanners. The following findings were recorded: liver echo-
structure and the size of liver, spleen, and portal vein. Liver histology, as recommended by an
international group, was morphologically categorised in chronic persistent hepatitis when
chronic inflammatory infiltrates were confined to the portal tracts with preserved lobular archi-
tecture and little or no fibrosis and with absent or slight piecemeal necrosis. Chronic active
hepatitis was categorised when chronic inflammatory infiltrates extended from the portal tract
into the parenchyma with piecemeal necrosis and eventually formation of intralobular septa.
Furthermore, we have defined as minimal liver disease those cases in which there was only a
minimal portal inflammatory infiltration with very mild hepatocyte necrosis. In 12 patients
liver biopsy was not performed as their parents did not give consent. Epidemiological, clinical,
histological, and laboratory features were compared between anti-HCV positive and anti-HCV
negative patients. Statistical analysis was performed by the Student's t, χ², and Fisher's exact
tests.

Results
Thirteen children (39%, nine boys, four girls, mean age 7-9 years, range 1-4-12-2 years) out of
33 children with chronic NANBH showed serological evidence of HCV infection. The male:female ratio was 2-25 in anti-HCV positive patients and 0-8 in anti-HCV negative patients
(p=0-15). Age at the diagnosis of chronic NANBH and type of onset were not statistically
different between anti-HCV positive and anti-HCV negative patients. None of the patients studied showed symptoms of liver disease, regardless of the HCV status. On physical
examination, hepatomegaly was found in eight out of 13 (61%) anti-HCV positive and in seven
out of 20 (35%) anti-HCV negative patients (p=0-12); hepatosplenomegaly was found in one
(8%) anti-HCV positive and in one (5%) anti-HCV negative patient (p=0-64). Nutritional
status was satisfactory for all the patients and in fact their weight was above the 90% of that
expected for their height (that is grade 0 malnutrition). All patients showed also a grade 0
for height stunting.

The route of infection of the patients studied is shown in table 1. Nine (27%) patients had received a blood transfusion before diagnosis of chronic NANBH was made (mean time 38
months, range 8-94 months). A history of blood

transfusion was significantly more common among the anti-HCV positive patients, whereas
in anti-HCV negative patients the source of infection was more commonly unknown. For
three patients (9%) a parenteral exposure was supposed, as they had undergone a surgical
procedure and there was a close chronological correlation between surgery and detection of
hypertransaminasemia.

Intrafamilial transmission of hepatitis could be suggested in four (12%) children: a vertical
transmission was clearly shown only in one child and in another two cases such trans-
mission could be supposed but not proved. Finally, a horizontal transmission was suggested
in one child whose father was affected by chronic hepatitis C. In none of the remaining
62 parents and in none of the 36 siblings tested evidence of NANBH or HCV infection was
found. At the time of the present study mean values of serum aspartate aminotransferase were
1-75 times the upper normal value (40 IU/l) (median 60 IU/l, range 28-143 IU/l), and those
of alanine aminotransferase were 3-3 times the upper normal value (40 IU/l) (median 83-5,
range 19-250 IU/l), with no significant difference between anti-HCV positive and anti-HCV
negative patients. Phases of normalisation of trans-
aminasemia were found in 17 (85%) anti-HCV negative patients and in three (18%) anti-HCV
positive patients (p=0-0005). The remaining anti-HCV positive patients showed, however,
fluctuating values of transaminases, which never fell within the normal range. Twenty two
patients (11 anti-HCV positive) were followed up for at least two years, and the profile of
alanine aminotransferase serum concentrations showed no significant difference between initial
and final values. The other tests of liver function were normal in all patients. Three (23%) out of
13 anti-HCV positive patients had no detectable amount of IgA in peripheral blood and IgG and
IgM serum concentrations were normal in all of them. Conversely, immunoglobulin concentra-
tions were within the normal range in all anti-
HCV negative patients.

Ultrasound scanning confirmed the hepatome-
galy and the hepatosplenomegaly found at clinical examination; no patient showed portal
hypertension or significant changes in liver echo-
structure. Liver biopsy was performed after a mean time of 2-8 years (range 0-5-7-5
years) from the diagnosis of chronic NANBH. With regard to clinical and biochemical features,
no difference was found between biopsied and non-biopsied patients. As it has been reported
that in NANBH liver damage is more severe in post-transfusion than in sporadic cases, the
patients studied were grouped according to their route of infection. In table 2 the histological
features of the patients biopsied are shown. Minimal liver disease was more frequent in anti-
HCV negative patients (p=0-02) and chronic active hepatitis in anti-HCV positive patients
(p=0-04). Histological features, considered characteristic of NANBH, such as lymphoid
were never found, but fatty degeneration was found in six (two anti-HCV positive) patients.

Table 1. Route to infection in 33 patients with chronic
NANBH in relation to HCV status

<table>
<thead>
<tr>
<th>Route to infection</th>
<th>Anti-HCV positive (n=13)</th>
<th>Anti-HCV negative (n=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood transfusion</td>
<td>7 (54)*</td>
<td>2 (10)*</td>
</tr>
<tr>
<td>Parenteral exposure</td>
<td>2 (15)</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Intrafamily transmission</td>
<td>3 (23)</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Unknown*</td>
<td>1 (7)</td>
<td>16 (80)**</td>
</tr>
</tbody>
</table>

*p=0-009; *p=0-0005.
*Unknown=clinical history negative for the above mentioned routes of infection.
Altogether the liver lesions of our patients were not very specific of NANBH. Finally, considering our patients according to the route of infection, independently by the HCV status, liver damage was not statistically different between post-transfusion and sporadic cases.

Discussion

Previous epidemiological studies suggest that there are, in the world, approximately 100 million non-A, non-B carriers, including anti-HCV positive subjects; for the majority no history of parenteral exposure is reported. In adulthood clinical features and outcome of NANBH, in particular the high propensity of patients to develop cirrhosis, and the role of HCV infection are already known. Our study, performed in consecutive patients, demonstrates that in childhood chronic NANBH is in most cases an asymptomatic disease, so that its real prevalence in the paediatric population is probably underestimated. Furthermore, we have found that, unlike that seen in adults, HCV plays a less important part as an aetiological agent of chronic NANBH. As the majority of the children with chronic NANBH showed no evidence of HCV infection, to identify NANBH with HCV infection appears, in childhood, unwarranted. Furthermore, considering that hepatitis A infection never becomes chronic, we think that the definition of 'chronic NANBH' for cases not related to HCV infection is incorrect, and we propose the term 'chronic non-B, non-C hepatitis'.

In our series, history of parenteral exposure was significantly more frequent among anti-HCV positive than anti-HCV negative children. As in anti-HCV negative patients no marker of viral infection is available and the majority of our patients with chronic non-B, non-C hepatitis had an unknown source of infection, the viral nature of the disease might also be in doubt. Alternatively, chronic non-B, non-C hepatitis could be caused by viral agent(s) that recognise a different mode of transmission. It is known that intrafamilial transmission does not play an important part in spreading NANBH, including HCV infection; conversely, contrasting data about vertical transmission have been reported. The results of the present study show that both these modes of transmission play a minor part.

As far as liver histology is concerned: in the children studied severe lesions were not found, whereas in adults cirrhosis is present in 20% of cases. It is worth noting that histological features, reported as peculiar of NANBH in adults (for example, lymphoid follicles and perportal inflammation) were not found in the children studied. Considering anti-HCV positive patients collectively, the degree of liver damage was higher when compared with the group of anti-HCV negative subjects, but no peculiar histological feature distinguishing the two groups was identified. Moreover, our results do not confirm the presence of more severe liver damage in patients with post-transfusion hepatitis, as reported by other authors. The lack of signs of cirrhosis in the children studied cannot be considered a positive prognostic index for the outcome of the disease, as cirrhosis can develop afterwards also in the absence of severe liver damage in the early phases of the disease. In fact, in contrast with what had previously been reported in children with chronic B hepatitis, in whom cirrhosis seems to be an early complication, in children with chronic NANBH the progression to cirrhosis might be related to the duration of disease. However, to support this hypothesis and to improve the knowledge of the natural history of the disease, longitudinal studies would be desirable.

We are however aware that such kind of study is at present ethically unjustifiable because of the promising results of interferon treatment. In conclusion, our study shows that chronic NANBH in children is characterised by a clinical picture and histological features that are different from those of adults. Therefore, it is interesting to study whether the minor histological lesions in children are dependent on the shorter duration of the disease or on a different age related host response to infection. Finally, as evidence of HCV infection has been found in anti-HCV negative patients by the polymerase chain reaction and detection of HCV antigen on liver tissue, the real role of HCV infection needs a further evaluation.


Chronic non-A, non-B hepatitis: role of hepatitis C virus.

R Iorio, S Guida, S Porzio, I Fariello and A Vegnente

Arch Dis Child 1993 68: 219-222
doi: 10.1136/adc.68.2.219

Updated information and services can be found at:
http://adc.bmj.com/content/68/2/219

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/